Activity of Selected Group of Monoterpenes in Alzheimer's Disease Symptoms in Experimental Model Studies-A Non-Systematic Review

Alzheimer's disease (AD) is the leading cause of dementia and cognitive function impairment. The multi-faced character of AD requires new drug solutions based on substances that incorporate a wide range of activities. Antioxidants, AChE/BChE inhibitors, BACE1, or anti-amyloid platelet aggregation substances are most desirable because they improve cognition with minimal side effects. Plant secondary metabolites, used in traditional medicine and pharmacy, are promising. Among these are the monoterpenes-low-molecular compounds with anti-inflammatory, antioxidant, enzyme inhibitory, analgesic, sedative, as well as other biological properties. The presented review focuses on the pathophysiology of AD and a selected group of anti-neurodegenerative monoterpenes and monoterpenoids for which possible mechanisms of action have been explained. The main body of the article focuses on monoterpenes that have shown improved memory and learning, anxiolytic and sleep-regulating effects as determined by in vitro and in silico tests-followed by validation in in vivo models.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:22

Enthalten in:

International journal of molecular sciences - 22(2021), 14 vom: 08. Juli

Sprache:

Englisch

Beteiligte Personen:

Wojtunik-Kulesza, Karolina [VerfasserIn]
Rudkowska, Monika [VerfasserIn]
Kasprzak-Drozd, Kamila [VerfasserIn]
Oniszczuk, Anna [VerfasserIn]
Borowicz-Reutt, Kinga [VerfasserIn]

Links:

Volltext

Themen:

Acetylcholine
Acetylcholinesterase
Alzheimer’s disease
Anti-Anxiety Agents
Anti-Inflammatory Agents
Antioxidants
Anxiolytic activity
Apolipoproteins E
Cholinesterase Inhibitors
EC 3.1.1.7
Insomnia
Iridoids
Journal Article
Memory
Monoterpenes
N9YNS0M02X
Nerve Tissue Proteins
Neuroprotective Agents
Nootropic Agents
Polyphenols
Review
Sleep regulatory

Anmerkungen:

Date Completed 17.08.2021

Date Revised 17.08.2021

published: Electronic

Citation Status MEDLINE

doi:

10.3390/ijms22147366

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM328438561